...
首页> 外文期刊>Neurosurgical focus >Association between timing of kyphoplasty and opioid prescribing risk after vertebral fracture
【24h】

Association between timing of kyphoplasty and opioid prescribing risk after vertebral fracture

机译:椎骨成形术时间与椎骨骨折后的阿片类药物的正常关系

获取原文
           

摘要

OBJECTIVE Approximately 550,000 Americans experience vertebral fracture annually, and most receive opioids to treat the resulting pain. Kyphoplasty of the fractured vertebra is a procedural alternative that may mitigate risks of even short-term opioid use. While reports of kyphoplasty’s impact on pain scores are mixed, no large-scale data exist regarding opioid prescribing before and after the procedure. This study was conducted to determine whether timing of kyphoplasty following vertebral fracture is associated with duration or intensity of opioid prescribing. METHODS This retrospective cohort study used 2001–2014 insurance claims data from a single, large private insurer in the US across multiple care settings. Patients were adults with vertebral fractures who were prescribed opioids and underwent balloon-assisted kyphoplasty within 4 months of fracture. Opioid overdose risk was stratified by prescribed average daily morphine milligram equivalents using CDC guidelines. Filled prescriptions and risk categories were evaluated at baseline and 90 days following kyphoplasty. RESULTS Inclusion criteria were met by 7119 patients (median age 77 years, 71.7% female). Among included patients, 3505 (49.2%) were opioid na?ve before fracture. Of these patients, 31.1% had new persistent opioid prescribing beyond 90 days after kyphoplasty, and multivariable logistic regression identified kyphoplasty after 8 weeks as a predictor (OR 1.34, 95% CI 1.02–1.76). For patients previously receiving opioids, kyphoplasty 4 weeks after fracture was associated with persistently elevated prescribing risk (OR 1.84, 95% CI 1.23–2.74). CONCLUSIONS New persistent opioid prescribing occurred in nearly one-third of patients undergoing kyphoplasty after vertebral fracture, although early treatment was associated with a reduction in this risk. For patients not na?ve to opioids before fracture diagnosis, early kyphoplasty was associated with less persistent elevation of opioid overdose risk. Subsequent trials must compare opioid use by vertebral fracture patients treated via operative (kyphoplasty) and nonoperative (ongoing opioid) strategies before concluding that kyphoplasty lacks value, and early referral for kyphoplasty may be appropriate to avoid missing a window of efficacy.
机译:客观约550,000名美国人每年体验椎骨骨折,大多数接受阿片类药物治疗所产生的疼痛。裂缝椎骨的脑膜术是一种程序替代方案,可能会减轻甚至短期阿片类药物使用的风险。虽然麦白成形术报告对疼痛评分的影响进行了混合,但在程序之前和之后没有存在关于阿片类药物的大规模数据。进行该研究以确定椎骨成形术后椎体骨折是否与阿片类药物规定的持续时间或强度相关。方法本次修队列研究使用2001-2014保险索赔数据来自美国的单一大型私人保险公司,跨越多个护理环境。患者是椎骨骨折的成年人,在骨折4个月内被规定的阿片类药物和接受球囊辅助脑膜成形术。使用CDC指南,通过规定的平均每日吗啡毫克当量分层阿片过量风险。填充的处方和风险类别在基线和脑骨成形术后90天评估。结果纳入标准由7119名患者(中位年龄77岁,女性女中位数为71.7%)。包括在内的患者中,在骨折之前,3505(49.2%)是阿片类药物Naα。在这些患者中,31.1%在脑膜成形术后90天内有新的持续性阿片类药物,而多变量逻辑回归在8周后确定了脑膜成形术(或1.34,95%CI 1.02-1.76)。对于以前接受阿片类药物的患者,骨髓成形术>骨折后4周与持续升高的处方风险(或1.84,95%CI 1.23-2.74)相关。结论椎骨骨折后近三分之一的脑膜成形术患者发生了新的持久性阿片类药物,尽管早期治疗与这种风险的降低有关。对于在骨折诊断前没有对阿片类药物的患者,早期的脑膜成形术与阿片类药物过量风险的较少持续升高有关。随后的试验必须通过手术(脑膜术)和非手术(持续的阿片类药物)策略进行比较Opioid使用,并且在得出结论之前,盲肠成形术缺乏价值,而脑膜成形术的早期转诊可能是适当的,以避免缺少效力窗口。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号